Press releases

(January 5, 2006) -- Boston Scientific Corporation (NYSE: BSX) announced today that President and Chief Executive Officer Jim Tobin has agreed to a request from the Board of Directors to extend...

New device pass-through code is only intended for use in the hospital outpatient setting under Medicare

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the year and fourth quarter ended December 31, 2005.

BEACH trial evaluated the benefits of carotid artery stenting (CAS) in conjunction with embolic protection for the treatment of carotid artery disease.

Boston Scientific Corporation (NYSE: BSX) today announced financial results for its third quarter ended September 30, 2005. Read the highlights.

(October 10, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company

New facility includes research and development labs, the Cardiovascular Technology and Product Development organization and other supporting functions.

New complex will serve as the new headquarters for the Company.

The twins took part in a groundbreaking study investigating the effectiveness of bilateral implants as a treatment for deafness in young children.

Award recognizes Company's successful efforts to increase efficiencies in the global supply chain.

"We are pleased with the second quarter results, which featured double digit growth on a global basis," said Jim Tobin, President and CEO.

Precision system is an implantable neurostimulator that masks pain signals.

Innovation represents the latest in treating brain aneurysm

A live webcast and replay of the Tuesday, July 19 session will be available. Learn how to tune in.

Johnson & Johnson's devices found to have infringed two Company patents

(June 27, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it is voluntarily recalling worldwide all Hemashield® VANTAGE™ Vascular Grafts, which are used in peripheral...

(June 24, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement agreement with the U.S. Department of Justice regarding the Department's...

(June 21, 2005) -- Boston Scientific Corporation (NYSE: BSX) announced today that a jury in a patent infringement case in U.S. District Court in Delaware brought by Johnson & Johnson (NYSE: JNJ)...

OLYMPIA registry plans to enroll more than 30,000 patients at more than 600 centers around the world.

Company completes final phase; Rubicon now a wholly-owned subsidiary.

A live webcast and replay of the Wednesday, June 15 session will be available. Learn how to tune in.

Dutch court rules that a subsidiary of Johnson & Johnson infringed a Boston Scientific balloon catheter patent.

Quinn will be responsible for Company-wide human resources efforts, supporting all businesses, regions and functions.

The Company announced the estimates at a meeting of financial analysts held in conjunction with the Paris Course on Revascularization (EuroPCR).

TAXUS V trial is studying the most challenging lesions and highest-risk patients ever studied in a randomized, controlled clinical trial in the United States.

Thirty-day safety data reported from global ATLAS clinical trial.

Clinical findings announced at the annual Paris Course on Revascularization.

Two-year follow-up data from TAXUS VI clinical trial consistent with results for slow-release TAXUS formulation.

Results presented are among the most comprehensive intravascular ultrasound (IVUS) follow-up data of any drug-eluting stent randomized clinical trial.

Research may signal new hope for the estimated 18.8 million Americans suffering from depression and four million from AD.

Extended expiration date applies to all sizes of the TAXUS system for sale in the United States.

The Paris Course on Revascularization (EuroPCR) runs from May 24 to 27; read the schedule highlights.

Results were presented in oral and poster sessions at the Digestive Disease Week (DDW) 2005 conference.

A live webcast and replay of the Tuesday, May 17 session will be available. Learn how to tune into the presentation.

A live webcast and replay of the May 3 conference session will be available. Learn how to tune in for the presentation.

BEACH study evaluates the effectiveness of stenting with embolic protection for patients at high risk for carotid endarterectomy (CEA), the surgical treatment for carotid artery disease.

April 19 edition of JACC is a special issue devoted to the TAXUS IV trial.

"This was another record quarter, thanks in large part to the ongoing success of TAXUS," said Jim Tobin, President and CEO.

Acquisition would bring devices and procedures for treating abdominal aortic aneurysms (AAA).

Company currently distributes CryoVascular's angioplasty device to treat atherosclerotic disease of the legs and other peripheral arteries.

NexStent™ recently received CE Mark for commercialization in Europe and certain other international markets.

Facility has received the prestigious NorthFace ScoreBoard Award for excellence in customer service for the second consecutive year.

SYNTAX trial will compare the performance of drug-eluting stents with cardiac surgery in the most complex patient subsets.

Award recognizes Company's accomplishments in creating a project-based system.

(April 7, 2005) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2005 on Tuesday, April 19, at 11:00...

A live webcast and replay of the April 12 conference session will be available.

Launch of Company's three large vessel TAXUS stent systems completes its line of sizes available in Europe and international markets.

With the indication, patients receiving the stent systems may safely undergo Magnetic Resonance Imaging (MRI) examination immediately following implantation.

Precision™ Spinal Cord Stimulation (SCS) System is a powerful new technology that provides many chronic pain sufferers a treatment option that is comfortable, long lasting and effective.

Company no longer markets or sells the NIR stent; findings will not affect Boston Scientific's ability to sell its market-leading TAXUS stent systems.